Skip to main content

Advertisement

Table 3 Success rates of the two groups

From: Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma

  2 weeks 1 month 3 months 6 months 12 months
Injection Group 95.2 % 90.5 % 80.0 % 73.7 % 72.2 %
(Successful subjects/total subjects) (20/21) (19/21) (16/20) (14/19) (13/18)
Control Group 90.9 % 81.8 % 77.3 % 71.4 % 68.4 %
(Successful subjects/total subjects) (20/22) (18/22) (17/22) (15/21) (13/19)
P 0.57 0.41 0.83 0.87 1.00
  1. Note: Success was defined as IOP > = 6 mm Hg and < = 21 mm Hg, with or without the use of anti-glaucoma medications, and without severe complications or reoperation. The differences in the success rates were compared between the two groups using the corrected chi-square test (two weeks, one month, and three months) and chi-square test (six months) and two-tailed Fisher’s exact test (12 months)